Aquestive Therapeutics, Inc. (AQST)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$5.34-0.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · AQST
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | 54.1 | 44.5 | 57.6 | 50.6 | 47.7 | 50.8 | 45.8 | 52.6 | 67.4 |
| Total Revenues | — | — | — | — | — | — | — | — | 67.4 |
| Cost of Revenues | 17.8 | 18.6 | 17.9 | 20.8 | 19.4 | — | 13.0 | — | — |
| Operating Expenses & Income | |||||||||
| Selling, General & Admin | 73.1 | 79.8 | 50.2 | 31.8 | 52.9 | 53.5 | 55.9 | 64.3 | 72.3 |
| R&D Expenses | 15.9 | 17.2 | 20.3 | 13.1 | 17.5 | 17.0 | 19.9 | 20.6 | 23.1 |
| Operating Income | (52.7) | (71.1) | (30.8) | (15.1) | (42.1) | (34.7) | (42.9) | (52.7) | (48.9) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | 11.1 | 11.1 | 6.3 | 6.6 | 10.0 | 11.1 | 9.3 | 7.7 |
| Interest & Investment Income | — | — | — | — | — | — | 0.1 | — | — |
| Net Interest Expenses | — | — | — | — | — | — | 10.9 | — | — |
| EBT, Incl. Unusual Items | (78.2) | (83.8) | (44.2) | (7.6) | (54.4) | (70.5) | (55.8) | (66.2) | (61.4) |
| Income Tax Expense | — | — | (0.0) | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||
| Net Income | (78.2) | (83.8) | (44.1) | (7.9) | (54.4) | (70.5) | (55.8) | (66.2) | (61.4) |
| Per Share | |||||||||
| Basic EPS | (0.63) | (0.78) | (0.51) | (0.13) | (1.12) | (1.85) | (1.66) | — | — |
| Diluted EPS | (0.63) | (0.78) | (0.51) | (0.13) | (1.12) | (1.85) | (1.66) | — | — |
| Revenue per Share | 0.43 | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 125.0 | 106.9 | 86.7 | 61.3 | 48.7 | 38.1 | 33.7 | — | — |
| Diluted Weighted Avg Shares | 125.0 | 106.9 | 86.7 | 61.3 | 48.7 | 38.1 | 33.7 | — | — |
| Supplemental | |||||||||
| EBITDA | — | (70.5) | (30.1) | (13.8) | (39.7) | (31.7) | (39.5) | (49.8) | (45.7) |
| EBIT | (52.7) | (71.1) | (30.8) | (15.1) | (42.1) | (34.7) | (42.9) | (52.7) | (48.9) |
| Effective Tax Rate | — | — | — | -3.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.